Global pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) compared to standard GnP alone Topline data readout, including primary ...
The first patient has been dosed with 64Cu-PD-29875 in a first-in-human clinical study in patients with gastric cancer.
Anocca AB (‘Anocca’ or the ‘Company’), a clinical-stage biotechnology company developing advanced T-cell immunotherapies, today announced the successful dosing of the first patients across multiple ...
HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion Medical, a therapeutic oncology company, today announced that the first patient has completed treatment with SCINTIX™ biology-guided radiotherapy on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results